Journal
JOURNAL OF CONTROLLED RELEASE
Volume 348, Issue -, Pages 250-263Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2022.05.057
Keywords
Hepatocellular carcinoma; Traditional herbal medicine; Biomimetic nanoformulation; cancer immunotherapy; Combination therapy
Funding
- Fundamental Research Funds for the Central Universities, China
- National Natural Science Foundation of China [81774240, 82074154]
- Youth Tip-top Talent program in Shanghai
- Shanghai University of Traditional Chinese Medicine
Ask authors/readers for more resources
This study confirmed the role of Plumbagin and Dihydrotanshinone I as inducers of immunogenic cell death in hepatocellular carcinoma (HCC) cells. The researchers developed a polymeric nanoparticle formulation that enhanced the delivery and tumor targeting of these drugs, leading to chemo-immunotherapeutic effects and significantly prolonged survival in HCC mice. This study provides a promising strategy for remodeling the immunosuppressive tumor microenvironment in liver cancer.
Hepatocellular carcinoma (HCC) is resistant to current immunotherapy. This poor outcome mainly results from the immunosuppressive characteristics of tumor microenvironment (TME). Accumulating evidence indicates that some chemotherapy agents trigger immunogenic cell death (ICD), providing a promising strategy to remodel the immunosuppressive TME. The role of Plumbagin (PLB, a naphthoquinone compound from Plumbago zeylanica L.) as the ICD inducer for HCC cells was confirmed in this study. Dihydrotanshinone I (DIH, a phenanthraquinone compound of Salvia miltiorrhiza) functioned as the ICD enhancer by generating the reactive oxygen species (ROS). A poly(D,L-lactic-co-glycolic acid) (PLGA)-based nanoparticle (NP) was used to co-encapsulate PLB, DIH and NH4HCO3 (a pH sensitive adjuvant). This NP was further coated with the mannose-inserted erythrocyte membrane to produce a nanoformulation. This nanoformulation significantly increased the half-life and tumor targeting of two drugs in orthotopic HCC mice, generating chemo-immunotherapeutic effects for reversal of immunosuppressive TME. Consequently, the biomimetic nanoformulation loaded with low doses of PLB and DIH achieved significantly longer survival of HCC mice, without causing toxic signs. Our study demonstrates a promising strategy for remodeling the immunosuppressive TME of liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available